# GRI BIO, INC. (GRI) · Edgar & Edgarette company card

> Gri Bio (GRI) saw revenue fall 100% in FY2021 to $0 million, operating margin null against a -3.8% median for pharmaceutical preparations, equity -58.2% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1824293 · fiscal year ended 2021-12-31 · 2 audited years read · [page](https://www.pops4.com/boards/company/GRI) · [JSON](https://www.pops4.com/boards/company/GRI.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | -100.0% |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -4788.0%) |
| Net margin | -Infinity% |
| Operating cash flow | −$8M |
| Capital spending | $0 |
| Free cash flow | −$8M |
| Cash | $4M |
| Long-term debt | — |
| Total assets | $8M |
| Total equity | −$5M |
| Equity ÷ assets | -58.2% |
| Return on equity | — |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -13.58 (distress zone)
- Piotroski F: 4 of 9 (middling)
- Health Harbor boat: Sound ship · one warning sign · operating cash flow was negative (-$10.2M in FY2025)

## Edgarette's reading

Exposure: revenue $0K (FY2021). Experience: revenue down 100.0% on the year; operating margin null, down from -4788.0%. Soundness: equity -58.2% of assets (liabilities exceed assets). Credibility: 2 audited years, moderate weight. Range: 80% of past cases like this landed between $0K and $0K next year (method v3, set from 749 SEC company-years; on a year the method never saw, 83% landed inside). A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median; growth -100.0% against 13.7%.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 2, latest 2026-01-16 ([filing](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000011/0001824293-26-000011-index.htm))

## Recent filings

- DEF 14A · filed 2026-09-28 · [filing](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000060/0001824293-26-000060-index.htm)
- 8-K · filed 2026-09-08 · 7.01 Regulation FD Disclosure; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000057/0001824293-26-000057-index.htm)
- 10-Q · filed 2026-08-14 · [filing](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000055/0001824293-26-000055-index.htm)
- 8-K · filed 2026-06-18 · 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000050/0001824293-26-000050-index.htm)
- 8-K · filed 2026-05-14 · 2.02 Results of Operations and Financial Condition; 8.01 Other Events; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000046/0001824293-26-000046-index.htm)
- 10-Q · filed 2026-05-13 · [filing](https://www.sec.gov/Archives/edgar/data/1824293/000182429326000044/0001824293-26-000044-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001824293.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1824293

## Cite

POPS4, Edgar & Edgarette: GRI BIO, INC. (GRI) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/GRI. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Its latest audited year is FY2025, which reports no revenue; the revenue figures and the range here are from FY2021, its last year with revenue on record. Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.